Clinical Trial Update: A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders [Phase 2]

View source ↗

Summary

Phase 2 study of anagrelide controlled release (GALE-401) for high platelet counts due to bone marrow disorders has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms
• Thrombocytosis

Drugs mentioned

• Anagrelide Controlled Release (GALE-401) (anagrelide)

Snippet

Sponsor: Galena Biopharma, Inc. | Conditions: Thrombocytosis, Myeloproliferative Neoplasms | Phase 2 | Status: COMPLETED